Argo Biopharma begins patient dosing in phase II trials of siRNA therapy BW-40202: Shanghai, China Wednesday, April 22, 2026, 15:00 Hrs [IST] Argo Biopharmaceutical Co., Ltd. (Arg ...
The treatment landscape of generalised myasthenia gravis, a prototypic antibody-mediated disorder of the neuromuscular junction, has considerably evolved in the past 8 years.1 The approval of targeted ...
Panakeia ("the Company"), the world's first in silico multi-omics company, today unveiled landmark pathway activation data in cancers at the American Association for Cancer Research (AACR) Annual ...
C3G and IC-MPGN can be difficult to diagnose because they are so rare and their symptoms are vague and nonspecific. A kidney biopsy is considered the gold standard and usually needed to confirm the ...
First patient dosed in Opti-GAIN, a first-in-human Phase I/II clinical trial of CTx001 in Geographic Atrophy secondary to AMD CTx001 is an investigational AAV-based gene therapy designed to deliver ...
Objective SLE is a systemic autoimmune disease in which the complement system plays a key pathogenic role, yet the ...
VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE)-- EnviroGold Global Limited (TSX-V: NVRO | OTCQB: ESGLF | FSE: YGK) ("EnviroGold” or the "Company”), a clean technology company focused on ...
Lake Erie College of Osteopathic Medicine (LECOM) is reinforcing its commitment to accessible and affordable pharmacy education by offering three fully accredited Doctor of Pharmacy (Pharm.D.) ...
Interac Corp. (Interac) is expanding the Interac® verification service through a new collaboration with National Bank of ...
Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced preclinical data highlighting an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results